Product Description
For the Treatment of Gram-negative Sepsis (Sourced from: https://clinicaltrials.gov/ct2/show/NCT00563134)
Mechanisms of Action: Gram- Bacteria Reducer
Novel Mechanism: Yes
Modality: N/A
Route of Administration: N/A
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Hospital Authority, Hong Kong
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description

Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
KW/FR/04-018 | N/A |
Suspended |
Sepsis|Gram-Negative Bacterial Infections |
None |